Lantern Pharma Establishes Manufacturing Network in Preparation for Its Phase 2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer and a Phase 1 Clinical Trial for Solid Tumors and Glioblastoma
- Monday, July 20, 2020, 7:21
- PR Newswire
- Add a comment
DALLAS, July 20, 2020 /PRNewswire/ — Lantern Pharma (NASDAQ: LTRN), a clinical stage biotechnology company focused on leveraging artificial intelligence (“A.I.”), machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit…
About the Author
admin has written 21717 stories on this site.